Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Dose Escalation and Expansion Study of Tucatinib in Combination With Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

NCT04430738 is registered in ClinicalTrials.gov with Seagen, a wholly owned subsidiary of Pfizer as lead sponsor.

NCT NCT04430738
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04430738 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Dose Escalation and Expansion Study of Tucatinib in Combination With Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 15, 2020
Completion date
December 31, 2026
Enrollment
40 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma, colorectal carcinoma, esophageal adenocarcinoma, gallbladder carcinoma, gastric adenocarcinoma, gej adenocarcinoma